Vytrus BiotechXMAD:VYT +0.57%69 Interest Coverage is 386.50 as of Dec. 2025, which is 10757% above its 10-year median of 3.56. GuruFocus rates XMAD:VYT with a GF Score™ of 69/100 and a GF Value™ of €5.54 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 377 Biotechnology companies, Vytrus Biotech ranks worse than 54.64% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Vytrus Biotech's
Operating Income
for the
six
months ended in Dec. 2025 was €1.55 Mil. Vytrus Biotech's Interest Expense for the
six
months ended in Dec. 2025 was €-0.00 Mil.
Vytrus Biotech's interest coverage for the quarter that ended in Dec. 2025 was 386.50.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Vytrus Biotech's Interest Coverage or its related term are showing as below:
XMAD:VYT'
s Interest Coverage Range Over the Past 10 Years
Min: 1.44 Med: 3.56 Max: 63.64
Current: 63.64
XMAD:VYT's Interest Coverage is ranked worse than 54.64% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs XMAD:VYT: 63.64
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Vytrus Biotech Interest Coverage Related Terms
Vytrus Biotech Interest Coverage Historical Data
* Premium members only.
The historical data trend for Vytrus Biotech's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
XMAD:VYT vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Vytrus Biotech's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vytrus Biotech Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vytrus Biotech's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Vytrus Biotech's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vytrus Biotech (XMAD:VYT) has a Interest Coverage of 386.50 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Vytrus Biotech and its competitors. This is 10757% above median its historical median of 3.56. Over the past decade, Vytrus Biotech's Interest Coverage has ranged from 1.44 to 63.64. According to the industry distribution chart, Vytrus Biotech ranks #206 out of 377 companies in the Biotechnology industry, placing it in the top 54.6%.
Is Vytrus Biotech's Interest Coverage too high?
Vytrus Biotech's current Interest Coverage of 386.50 is 10757% above median its 10-year median of 3.56. Over the past 10 years, this metric has ranged from a low of 1.44 to a high of 63.64. The Biotechnology industry median Interest Coverage is 106.07. Vytrus Biotech's value of 386.50 is 264.4% above this industry median. Based on the distribution chart, Vytrus Biotech ranks #206 out of 377 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vytrus Biotech has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vytrus Biotech's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vytrus Biotech ranks #206 out of 377 companies for Interest Coverage. This places Vytrus Biotech in the lower half of its industry. The industry median Interest Coverage is 106.07. Vytrus Biotech's value of 386.50 is 264.4% above this benchmark. Historically, Vytrus Biotech's own Interest Coverage has ranged from 1.44 to 63.64 over the past decade. While the company's 10-year median is 3.56 vs. the industry median of 106.07, Vytrus Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vytrus Biotech's current Interest Coverage of 386.50 is 264.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Vytrus Biotech and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vytrus Biotech's current Interest Coverage is 386.50, which is 10757% above median its own 10-year median of 3.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vytrus Biotech stock overvalued right now?
Based on GuruFocus' analysis, Vytrus Biotech (XMAD:VYT) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.54, compared to a current price of €17.50 — trading 215.9% above its estimated fair value. The current Interest Coverage is 386.50, which is 10757% above median its 10-year median of 3.56 and 264.4% above the Biotechnology industry median of 106.07. Vytrus Biotech's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Vytrus Biotech (XMAD:VYT), the current Interest Coverage is 386.50 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vytrus Biotech (XMAD:VYT) Overvalued in 2026?
Based on GuruFocus' analysis, Vytrus Biotech stock appears to be overvalued.
The current stock price of €17.50 is trading 215.9% above its estimated GF Value™ of €5.54.
GuruFocus considers Vytrus Biotech to be Significantly Overvalued.
Key valuation signals for XMAD:VYT:
Interest Coverage: 386.50 (10757% above median its 10-year median of 3.56)
GF Value™: €5.54 vs. price of €17.50 (215.9% above fair value)
Industry Position: 264.4% above the Biotechnology median (#206 of 377)
No single metric tells the full story. See the XMAD:VYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
69GF Score
Get the complete analysis for XMAD:VYT
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:VYT has been successfully added to your 
